0001018735false--12-31Q1202200P0Y00010187352022-01-012022-03-310001018735nymox:SubsequentEventsMember2022-04-290001018735nymox:JamesGRobinsonMember2022-01-012022-03-310001018735nymox:JamesGRobinsonMember2022-03-310001018735nymox:ChiefFinancialOfficersMember2021-01-012021-03-310001018735nymox:CorporateLegalCounselMember2021-01-012021-03-310001018735nymox:ChiefFinancialOfficersMember2022-01-012022-03-310001018735nymox:CorporateLegalCounselMember2022-01-012022-03-310001018735nymox:DirectorMember2021-01-012021-03-310001018735nymox:DirectorMember2022-01-012022-03-310001018735nymox:JanuaryOneTwoZeroOneNineMember2022-01-012022-03-310001018735nymox:JanuaryOneTwoZeroOneNineMember2022-03-310001018735nymox:StockOptionsMember2022-01-012022-03-310001018735nymox:PrivatePlacementsMember2022-01-012022-03-310001018735nymox:PrivatePlacementsMember2022-03-310001018735nymox:PrivatePlacementsMember2019-03-310001018735nymox:PrivatePlacementsMember2019-01-012019-03-310001018735nymox:PrivatePlacementsMember2021-01-012021-06-300001018735nymox:StockOptionsMember2022-03-310001018735nymox:PrivatePlacementsMember2021-06-300001018735nymox:StockOptionMember2021-01-012021-03-310001018735nymox:TwoThousandTwentyMember2022-01-012022-03-310001018735nymox:TwoThousandTwentyMember2021-01-012021-03-310001018735nymox:TwoThousandFifteenMember2022-01-012022-03-310001018735nymox:TwoThousandFifteenMember2021-01-012021-03-310001018735nymox:StockOptionMember2022-01-012022-03-310001018735ifrs-full:RetainedEarningsMember2022-03-310001018735nymox:AdditionalPaidInCapitalMember2022-03-310001018735nymox:ShareCapitalSubscriptionMember2022-03-310001018735nymox:CommonStockMember2022-03-310001018735ifrs-full:RetainedEarningsMember2022-01-012022-03-310001018735nymox:AdditionalPaidInCapitalMember2022-01-012022-03-310001018735nymox:ShareCapitalSubscriptionMember2022-01-012022-03-310001018735nymox:CommonStockMember2022-01-012022-03-310001018735ifrs-full:RetainedEarningsMember2021-12-310001018735nymox:AdditionalPaidInCapitalMember2021-12-310001018735nymox:ShareCapitalSubscriptionMember2021-12-310001018735nymox:CommonStockMember2021-12-310001018735ifrs-full:RetainedEarningsMember2021-03-310001018735nymox:AdditionalPaidInCapitalMember2021-03-310001018735nymox:ShareCapitalSubscriptionMember2021-03-310001018735nymox:CommonStockMember2021-03-310001018735ifrs-full:RetainedEarningsMember2021-01-012021-03-310001018735nymox:AdditionalPaidInCapitalMember2021-01-012021-03-310001018735nymox:ShareCapitalSubscriptionMember2021-01-012021-03-310001018735nymox:CommonStockMember2021-01-012021-03-310001018735ifrs-full:RetainedEarningsMember2020-12-310001018735nymox:AdditionalPaidInCapitalMember2020-12-310001018735nymox:ShareCapitalSubscriptionMember2020-12-310001018735nymox:CommonStockMember2020-12-3100010187352021-03-3100010187352020-12-3100010187352021-12-3100010187352022-03-3100010187352021-01-012021-03-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure
FORM 6-K
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Report of Foreign Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the period ended March 31, 2022
Commission File Number: 001-12033
Nymox Pharmaceutical Corporation |
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(l): ☐
Indicate by check mark if the registrant is submitting Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby
furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-______________
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| NYMOX PHARMACEUTICAL CORPORATION | |
| (Registrant) | |
| | | |
| By: | /s/ Paul Averback, MD | |
| | Paul Averback, MD | |
| | President and Chief Executive Officer | |
Date: May 13, 2022
